Composition for treating hyperlipemia

A technology for hyperlipidemia and a composition, which is applied in the field of treatment of hyperlipidemia, can solve the problems of delayed disease treatment, single action mechanism, limited antihypertensive effect, etc., and achieves convenient use, long duration of curative effect and good comprehensive effect. Effect

Inactive Publication Date: 2003-06-25
LUNAN PHARMA GROUP CORPORATION
View PDF0 Cites 61 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] The above two drugs have good curative effect as blood lipid-lowering drugs in the treatment of hyperlipidemia, but the mechanism of action

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition for treating hyperlipemia
  • Composition for treating hyperlipemia
  • Composition for treating hyperlipemia

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0031] Acipimus 250g

[0032] Lactose 30g

[0033] Sodium carboxymethyl starch 30g

[0034] Microcrystalline Cellulose 18g

[0035] 6% PVP in absolute ethanol 100g

[0036] Magnesium Stearate 2g

[0037] Preparation process: Acipimox is passed through a 100-mesh sieve, lactose, sodium carboxymethyl starch, and microcrystalline cellulose are passed through a 80-mesh sieve, and the prescribed amount of acipimox, lactose, sodium carboxymethyl starch, and microcrystalline cellulose is weighed Mix the ingredients evenly, add an appropriate amount of 6% PVP absolute ethanol solution to granulate, dry at 60°C, sieve the dry granules with a 16-mesh sieve, and add the prescribed amount of magnesium stearate to the dry granules. b.

[0038] Lovastatin 10g

[0039] Hydroxypropyl Cellulose 30g

[0040] 20g pregelatinized starch

[0041] 6% PVP in absolute ethanol solution 50g

[0042] Glyceryl B...

example 2

[0045] Acipimus 375g

[0046] Hydroxypropyl Methyl Cellulose-4M 40g

[0047] Microcrystalline Cellulose 30g

[0048] 8% PVP in absolute ethanol solution 150g

[0049] Magnesium Stearate 2g

[0050] Preparation process: Acipimox passes through a 100-mesh sieve, hydroxypropyl methylcellulose-4M and microcrystalline cellulose pass through a 80-mesh sieve, and the prescribed amount of acipimox and hydroxypropylmethylcellulose-4M is weighed , the microcrystalline cellulose is mixed evenly, add the absolute ethanol solution of 8%PVP and granulate in right amount, 60 ℃ of drying, 16 mesh sieve dry granules, add the magnesium stearate of recipe quantity in the dry granules. b.

[0051] Lovastatin 10g

[0052] Sodium Carboxymethyl Cellulose 30g

[0053] Lactose 20g

[0054] 6% PVP in 95% ethanol solution 50g

[0055] Magnesium Stearate 2g

[0056] Preparation process: Lovastatin passes through a 10...

example 3

[0058] Niacin 500g

[0059] Mannitol 10g

[0060] Lactose 40g

[0061] Microcrystalline Cellulose 20g

[0062] 6% PVP in 95% ethanol solution 120g

[0063] Magnesium Stearate 2g

[0064] Preparation process: niacin is passed through a 100-mesh sieve, mannitol, lactose, and microcrystalline cellulose are passed through a 80-mesh sieve, and the prescribed amount of niacin, mannitol, lactose, and microcrystalline cellulose is weighed and mixed evenly, and 95% of 6% PVP is added. An appropriate amount of % ethanol solution is granulated, dried at 60° C., and the dry granules are sieved with a 16-mesh sieve, and the prescribed amount of magnesium stearate is added to the dry granules. b.

[0065] Lovastatin 10g

[0066] 25g pregelatinized starch

[0067] Mannitol 25g

[0068] 6% PVP in 95% ethanol solution 50g

[0069] Micronized silica gel 2g

[0070] Preparation process: pass lovasta...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The composition for treating hyperlipemia contains one or more nicotinic acids or the derivatives and one or more Tatin compound as 3-hydroxy-3-methyl glutaryl coenzyme inhibitor in the effective amount and the active component weight ratio of 5-100 as well as medicinal supplementary material. The present invention is used in preventing and treating hyperlipemia and has long acting period and high comprehensive treating effect.

Description

Technical field [0001] The present invention relates to the treatment of hyperlipidemia, in particular provides a treatment of hyperlipidemia niacin, or its derivatives and 3-hydroxy-3-methylglutaryl coenzyme A (3-hydroxy-3-methylglutaryl-coenzyme A, Compositions of HMG-CoA) reductase inhibitors. The novel niacin with pharmaceutically active substances, or the combination of its derivatives and HMG-CoA reductase inhibitors can be used in the prevention and treatment of hyperlipidemia. Background technique [0002] The main place where the body synthesizes endogenous cholesterol is in the liver (accounting for about 70% of the total). The biosynthesis of cholesterol begins with the condensation of two molecules of acetyl-CoA into acetoacetyl-CoA, which is condensed with one molecule of acetyl-CoA into HMG CoA through the action of hydroxymethylglutaryl-CoA synthase in the cytosol. HMG CoA reductase in the cytosol can catalyze the reduction of HMG CoA with a ring-opening hyd...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/31A61K31/455A61K31/495A61P3/06
CPCA61K31/495A61K31/455A61K31/31A61P3/06A61K2300/00
Inventor 孙勇
Owner LUNAN PHARMA GROUP CORPORATION
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap